Mikael Eriksson
51 – 60 of 154
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
Trusted computing for infrastructure
Eriksson, Mikael LU
; Pourzandi, Makan
and Smeets, Ben
LU
(2014)
In Ericsson Review (English Edition)
91(2).
p.20-27
- Contribution to specialist publication or newspaper › Specialist publication article
- 2013
-
Mark
Benefits and Adverse Events in Younger Versus Older Patients Receiving Neoadjuvant Chemotherapy for Osteosarcoma: Findings From a Meta-Analysis.
- Contribution to journal › Article
-
Mark
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
- Contribution to journal › Article
- 2012
-
Mark
Pesticide exposure in farming and forestry and the risk of uveal melanoma
Behrens, Thomas ; Lynge, Elsebeth ; Cree, Ian ; Lutz, Jean-Michel ; Eriksson, Mikael LU
; Guenel, Pascal
; Merletti, Franco
; Morales-Suarez-Varela, Maria
; Afonso, Noemia
and Stengrevics, Aivars
, et al.
(2012)
In Cancer Causes and Control
23(1).
p.141-151
- Contribution to journal › Article
-
Mark
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Geisler, Christian H. ; Kolstad, Arne ; Laurell, Anna ; Jerkeman, Mats LU ; Raty, Riikka ; Andersen, Niels S. ; Pedersen, Lone B. ; Eriksson, Mikael LU
; Nordstrom, Marie
and Kimby, Eva
, et al.
(2012)
In British Journal of Haematology
158(3).
p.355-362
- Contribution to journal › Article
-
Mark
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy
Riihijarvi, Sari ; Nurmi, Heidi ; Holte, Harald ; Bjorkholm, Magnus ; Fluge, Oystein ; Pedersen, Lars Moller ; Fjordén, Karin LU ; Jerkeman, Mats LU ; Eriksson, Mikael LU
and Leppa, Sirpa
(2012)
In European Journal of Haematology
89(5).
p.395-402
- Contribution to journal › Article
-
Mark
Occupational exposure to endocrine-disrupting chemicals and the risk of uveal melanoma
Behrens, Thomas ; Lynge, Elsebeth ; Cree, Ian ; Lutz, Jean-Michel ; Eriksson, Mikael LU
; Guenel, Pascal
; Merletti, Franco
; Morales-Suarez-Varela, Maria
; Afonso, Noemia
and Stengrevics, Aivars
, et al.
(2012)
In Scandinavian Journal of Work, Environment and Health
38(5).
p.476-483
- Contribution to journal › Article
-
Mark
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor : A Randomized Trial
Joensuu, Heikki ; Eriksson, Mikael LU
; Hall, Kirsten Sundby
; Hartmann, Joerg T.
; Pink, Daniel
; Schuette, Jochen
; Ramadori, Giuliano
; Hohenberger, Peter
; Duyster, Justus
and Al-Batran, Salah-Eddin
, et al.
(2012)
In JAMA: The Journal of the American Medical Association
307(12).
p.1265-1272
- Contribution to journal › Article
-
Mark
Adjuvant therapy in primary GIST: state-of-the-art
Reichardt, P. ; Blay, J. -Y. ; Boukovinas, I. ; Brodowicz, T. ; Broto, J. M. ; Casali, P. G. ; Decatris, M. ; Eriksson, Mikael LU
; Gelderblom, H.
and Kosmidis, P.
, et al.
(2012)
In Annals of Oncology
23(11).
p.2776-2781
- Contribution to journal › Scientific review
-
Mark
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation
Luksch, R. ; Tienghi, A. ; Hall, K. Sundby ; Fagioli, F. ; Picci, P. ; Barbieri, E. ; Gandola, L. ; Eriksson, Mikael LU
; Ruggieri, P.
and Daolio, P.
, et al.
(2012)
In Annals of Oncology
23(11).
p.2970-2976
- Contribution to journal › Article